Compare ADPT & ANDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | ANDE |
|---|---|---|
| Founded | 2009 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Farming/Seeds/Milling |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 2019 | 2005 |
| Metric | ADPT | ANDE |
|---|---|---|
| Price | $14.54 | $73.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | $17.78 | ★ $75.00 |
| AVG Volume (30 Days) | ★ 2.0M | 295.5K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.08% |
| EPS Growth | ★ 63.89 | 12.93 |
| EPS | N/A | ★ 0.82 |
| Revenue | $276,976,000.00 | ★ $11,008,928,000.00 |
| Revenue This Year | $3.98 | $7.28 |
| Revenue Next Year | $22.72 | $3.57 |
| P/E Ratio | ★ N/A | $90.37 |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $6.77 | $31.03 |
| 52 Week High | $20.76 | $75.69 |
| Indicator | ADPT | ANDE |
|---|---|---|
| Relative Strength Index (RSI) | 52.25 | 58.80 |
| Support Level | $12.19 | $62.29 |
| Resistance Level | $17.72 | $73.97 |
| Average True Range (ATR) | 0.99 | 2.30 |
| MACD | 0.14 | -0.07 |
| Stochastic Oscillator | 70.42 | 61.64 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Andersons Inc is an agriculture and renewable fuels company. Its operations are classified into two reportable business segments: Agribusiness, which generates maximum revenue, and Renewables. The Agribusiness segment includes merchandising and managing logistics across various commodities, as well as being a manufacturer, distributor, and retailer of agricultural and related plant nutrients. The segment specializes in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. The Renewables segment mainly produces, purchases, and sells ethanol and co-products. Geographically, the company generates maximum revenue from the United States, followed by Canada, Mexico, and other markets.